A Double-blind, Placebo-controlled, Randomized, Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Oral Dose of MYMD1 Capsules in Healthy Male and Female Adult Subjects
Latest Information Update: 30 Jul 2024
At a glance
- Drugs Isomyosamine (Primary)
- Indications Lymphomatous thyroiditis; Rheumatoid arthritis; Sarcopenia; Thyroiditis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors MyMD Pharmaceuticals; TNF Pharmaceuticals
- 22 Jul 2024 According to TNF Pharmaceuticals media release, MyMD Pharmaceuticals, Inc changed its name to TNF Pharmaceuticals, Inc.
- 06 Dec 2022 According to a MyMD Pharmaceuticals media release, data from the trial will be presented at the 2022 British Society for Immunology (BSI) Congress.
- 14 Nov 2022 According to a MyMD Pharmaceuticals media release, results from the trial have been published in a peer-reviewed journal, Drug Research.